Trailhead Biosystems develops iPSC-derived human cells for drug discovery and cell-based therapies, utilizing the High-Dimensional Design of Experiments (HD-DoE) platform to optimize cell growth and differentiation. Their products, such as the TrailBio® Endothelial Cell Kit and Pre-Myelinating Oligodendrocyte Kit, provide reliable solutions for vascular biology research and myelination studies, addressing the need for precise cellular models in regenerative medicine.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery and cell-based therapies require precise and reliable human cell models, but traditional cell differentiation methods often lack the consistency and control needed for accurate research and therapeutic applications. Manual processes and variability in cell growth and differentiation can lead to inconsistent results and hinder the development of effective treatments.
Solution
Trailhead Biosystems provides high-quality, induced pluripotent stem cell (iPSC)-derived human cells optimized for drug discovery and cell-based therapies. The company utilizes a proprietary High-Dimensional Design of Experiments (HD-DoE) platform to systematically explore and optimize cell growth and differentiation processes. This data-driven approach enables precise control over cell fate, resulting in improved cell purity and consistency. Trailhead Biosystems' products offer researchers and therapeutic developers reliable and well-defined cellular models for advancing regenerative medicine and personalized healthcare.
Target Audience
The primary customers are researchers in vascular biology, neuroscience, and regenerative medicine, as well as pharmaceutical companies and therapeutic developers seeking reliable human cell models for drug discovery and cell-based therapies.
Features
- iPSC-derived cells for various applications, including vascular biology research, myelination studies, and drug testing.
- HD-DoE platform for data-driven, unbiased determination of critical process parameters.
- Advanced method analyzes multiple variables to efficiently optimize cell growth and differentiation.
- Robotics-assisted processes improve cell purity and enable cost-effective manufacturing.
- Available cell kits include TrailBio® Endothelial Cell Kit and TrailBio® Pre-Myelinating Oligodendrocytes Kit.
- Custom iPSC differentiation services are offered for specific research needs.